Harrow and iOR Partners Expand National Product Supply Agreement

Harrow and iOR Partners jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

“We are thrilled to be working alongside iOR Partners as they mobilize an increasing number of cataract surgeons to perform surgery in an office-based environment, offering more personalized care in a patient-friendly setting,” Mark L. Baum, Chairman and CEO of Harrow, said in a company news release. “iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality. Our mission has always focused on making medications accessible and affordable, and working with iOR Partners, the national leader in this fast-growing area of ophthalmic surgery, represents an important and growing channel for Harrow to meet our mission.”

“Harrow, through its ImprimisRx division, is the gold standard in supplying innovative compounded ophthalmic formulations that meet the highest federal manufacturing standards. Their commitment to quality, exceptional customer service, and the breadth of their portfolio are why we chose them as our partner,” said Tony Burns, Founder and Principal of iOR Partners. “These qualities support our confidence that we are delivering on our promise of personalized care that’s safe and comfortable for patients.”